AU2019437385B2 - Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer - Google Patents

Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer Download PDF

Info

Publication number
AU2019437385B2
AU2019437385B2 AU2019437385A AU2019437385A AU2019437385B2 AU 2019437385 B2 AU2019437385 B2 AU 2019437385B2 AU 2019437385 A AU2019437385 A AU 2019437385A AU 2019437385 A AU2019437385 A AU 2019437385A AU 2019437385 B2 AU2019437385 B2 AU 2019437385B2
Authority
AU
Australia
Prior art keywords
cancer
cbz
carcinoma
drug
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019437385A
Other languages
English (en)
Other versions
AU2019437385A1 (en
Inventor
Kjersti Flatmark
Karianne Giller Fleten
Heidi Johnsen
Yrr MØRCH
Ruth Schmid
Per Stenstad
Einar SULHEIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oslo University Hospital
SINTEF TTO AS
Original Assignee
Oslo University Hospital
SINTEF TTO AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo University Hospital, SINTEF TTO AS filed Critical Oslo University Hospital
Publication of AU2019437385A1 publication Critical patent/AU2019437385A1/en
Application granted granted Critical
Publication of AU2019437385B2 publication Critical patent/AU2019437385B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019437385A 2018-03-27 2019-09-26 Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer Active AU2019437385B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NO20180429 2018-03-27
US16/366,596 2019-03-27
US16/366,596 US11806330B2 (en) 2018-03-27 2019-03-27 PACA and cabazitaxel for anti-cancer treatment
PCT/EP2019/076121 WO2020192950A1 (en) 2018-03-27 2019-09-26 Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer

Publications (2)

Publication Number Publication Date
AU2019437385A1 AU2019437385A1 (en) 2021-11-04
AU2019437385B2 true AU2019437385B2 (en) 2025-04-10

Family

ID=66049182

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019437385A Active AU2019437385B2 (en) 2018-03-27 2019-09-26 Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer

Country Status (8)

Country Link
US (3) US20210113482A1 (cg-RX-API-DMAC7.html)
EP (2) EP3773471A1 (cg-RX-API-DMAC7.html)
JP (2) JP7317038B2 (cg-RX-API-DMAC7.html)
CN (2) CN111989087A (cg-RX-API-DMAC7.html)
AU (1) AU2019437385B2 (cg-RX-API-DMAC7.html)
BR (2) BR112020019452A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134923A1 (cg-RX-API-DMAC7.html)
WO (2) WO2019185685A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433846B2 (en) 2019-03-27 2025-10-07 Sintef Tto As Drug delivery system for treatment of cancer
CN111989087A (zh) 2018-03-27 2020-11-24 新泰福托特股份有限公司 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒
JP7461932B2 (ja) * 2018-08-23 2024-04-04 シンテフ ティーティーオー エイエス ナノ粒子
KR20230031188A (ko) * 2020-02-26 2023-03-07 바이오써젠 에이에스 치료적 폴리엔 마크롤리드의 제약 조성물 및 그의 사용 방법
GB202501169D0 (en) 2025-01-27 2025-03-12 Sintef Tto As Methods of producing polymeric particles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014191502A1 (en) * 2013-05-28 2014-12-04 Sinvent As Process for preparing stealth nanoparticles
CN107115532A (zh) * 2016-02-24 2017-09-01 首都医科大学宣武医院 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途
WO2018060437A1 (en) * 2016-09-29 2018-04-05 Sintef Tto A new drug delivery system for treatment of disease
NO342271B1 (en) * 2016-09-29 2018-04-30 Sintef Tto As A new drug delivery system for treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872703B1 (fr) 2004-07-07 2006-10-06 Ethypharm Sa Nanoparticules polymeriques composites
JP2008542293A (ja) 2005-05-23 2008-11-27 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 超音波増強ナノ粒子媒介性薬物送達のためのエコー形成性マイクロバブルおよびマイクロエマルジョン
EP1876188A1 (en) 2006-07-04 2008-01-09 NanoDel Technologies GmbH Two step miniemulsion process
US8679539B2 (en) * 2007-01-31 2014-03-25 Tong Shen Enterprise Co., Ltd. Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
FR2921660B1 (fr) 2007-10-01 2015-09-25 Centre Nat Rech Scient Nanoparticules hybrides organiques inorganiques a base de carboxylates de fer.
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
ES2424476T3 (es) 2011-03-31 2013-10-02 Bioalliance Pharma Nanopartículas cargadas con fármaco antitumoral quimioterápico
US20150343079A1 (en) 2012-10-25 2015-12-03 Sogang University Research Foundation Ultrasound contrast agent with nanoparticles including drug and method for preparing the same
US10391185B2 (en) 2014-11-26 2019-08-27 Fujifilm Visualsonics, Inc. Multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles
WO2016134115A1 (en) 2015-02-20 2016-08-25 Trustees Of Boston University Theranostic compositions and uses thereof
EP3316871A4 (en) * 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF
US20170071866A1 (en) * 2015-09-14 2017-03-16 Onxeo S.A. Nanoparticles loaded with active ingredients, their process of preparation, and their uses
WO2017046037A1 (en) * 2015-09-14 2017-03-23 Onxeo Nanoparticles loaded with active ingredients, their process of preparation and their uses
US10980826B2 (en) * 2015-11-06 2021-04-20 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR102803158B1 (ko) * 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
KR20170133257A (ko) 2016-05-24 2017-12-05 한양대학교 산학협력단 항암제 함유 나노입자를 포함하는 뇌질환 치료를 위한 비강 투여용 약제학적 조성물
CN111989087A (zh) * 2018-03-27 2020-11-24 新泰福托特股份有限公司 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒
US12433846B2 (en) 2019-03-27 2025-10-07 Sintef Tto As Drug delivery system for treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014191502A1 (en) * 2013-05-28 2014-12-04 Sinvent As Process for preparing stealth nanoparticles
CN107115532A (zh) * 2016-02-24 2017-09-01 首都医科大学宣武医院 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途
WO2018060437A1 (en) * 2016-09-29 2018-04-05 Sintef Tto A new drug delivery system for treatment of disease
NO342271B1 (en) * 2016-09-29 2018-04-30 Sintef Tto As A new drug delivery system for treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FUSSER MARKUS ET AL: JOURNAL OF CONTROLLED RELEASE, vol. 293, 4 December 2018 (2018-12-04), pages 183 - 192, XP085570318, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2018.11.029 *
HONGXIA LU ET AL: CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 59, no. 2, 23 May 2006 (2006-05-23), pages 175 - 181, XP019459213, ISSN: 1432-0843, DOI: 10.1007/S00280-006-0256-Z *
KOBAYASHI DAISUKE ET AL: GASTRIC CANCER, SPRINGER JAPAN, TOKYO, vol. 20, no. 1, 1 November 2016 (2016-11-01), pages 111 - 121, XP036351274, ISSN: 1436-3291, [retrieved on 20161101], DOI: 10.1007/S10120-016-0662-9 *
SOFIE SNIPSTAD ET AL: ULTRASOUND IN MEDICINE AND BIOLOGY., vol. 43, no. 11, 1 November 2017 (2017-11-01), US, pages 2651 - 2669, XP055595837, ISSN: 0301-5629, DOI: 10.1016/j.ultrasmedbio.2017.06.029 *
TAKAO KAMEI ET AL: CANCER SCIENCE, vol. 102, no. 1, 13 October 2010 (2010-10-13), JP, pages 200 - 205, XP055652047, ISSN: 1347-9032, DOI: 10.1111/j.1349-7006.2010.01747.x *

Also Published As

Publication number Publication date
BR112020019452A2 (pt) 2021-01-05
JP7550167B2 (ja) 2024-09-12
US20200061019A1 (en) 2020-02-27
JP7317038B2 (ja) 2023-07-28
EP3946253A1 (en) 2022-02-09
CN111989087A (zh) 2020-11-24
WO2019185685A1 (en) 2019-10-03
US11806330B2 (en) 2023-11-07
EP3773471A1 (en) 2021-02-17
US20190298682A1 (en) 2019-10-03
AU2019437385A1 (en) 2021-11-04
JP2022527858A (ja) 2022-06-06
WO2020192950A1 (en) 2020-10-01
US20210113482A1 (en) 2021-04-22
CA3134923A1 (en) 2020-10-01
CN113840594A (zh) 2021-12-24
JP2021519323A (ja) 2021-08-10
BR112021019003A2 (pt) 2021-11-30

Similar Documents

Publication Publication Date Title
JP7550167B2 (ja) がんの治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子
Ma et al. Polymeric nanomedicines for poorly soluble drugs in oral delivery systems: An update
Liu et al. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles
Li et al. Ultrasound triggered drug release from 10-hydroxycamptothecin-loaded phospholipid microbubbles for targeted tumor therapy in mice
Pan et al. Recent advances in boosting EGFR tyrosine kinase inhibitors-based cancer therapy
Zhu et al. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation
ES2890662T3 (es) Composiciones farmacéuticas, preparación y usos de las mismas
Yurgel et al. Developments in the use of nanocapsules in oncology
Xiong et al. Enhanced effect of folated pluronic F87-PLA/TPGS mixed micelles on targeted delivery of paclitaxel
Han et al. Free paclitaxel-loaded E-selectin binding peptide modified micelle self-assembled from hyaluronic acid-paclitaxel conjugate inhibit breast cancer metastasis in a murine model
JP7164205B2 (ja) キナ酸修飾ナノ粒子およびその使用
Zhou et al. Alternative and injectable preformed albumin-bound anticancer drug delivery system for anticancer and antimetastasis treatment
Chen et al. Recent progress in nanoformulations of cabazitaxel
Shen et al. Targeted sustained delivery of antineoplastic agent with multicomponent polylactide stereocomplex micelle
Soni et al. Polymeric Micelles in Targeted Breast Cancer Therapy: Recent Advances and Future Trends.
Xiong et al. A liposomal etoposide with a sustained drug release effectively alleviated the therapy-related leukemia
US12433846B2 (en) Drug delivery system for treatment of cancer
Enteshari et al. Antitumor activity of raloxifene-targeted poly (styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice
Rathee et al. Nanotechnology in drug delivery
Mahmood et al. Engineered liposomal nanoparticles and their medical applications
Alavi et al. Nanocarrier system for increasing the therapeutic efficacy of oxaliplatin
Indermun et al. Can Nanomedicinal Approaches Provide an Edge to the Efficacy of Tyrosine Kinase Inhibitors?
Raslan et al. Clinical translation of polymeric micelles into market
EP3395370B1 (en) Liposome and liposome composition
Mukherjee et al. Future direction of nanotherapy in the management of hepatocellular carcinoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)